US4761402A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for prophylactic and therapeutic treatment of infections
Assignee: Bioglucans LP
•
Filing: 1987-02-10
•
Granted: 1988-08-02
•
Expires: 2007-02-10
Abstract
Abstract A new class of soluble phosphorylated glucans is described as well as the process for making the same. According to one embodiment, the soluble phosphorylated glucan is derived from the yeast Saccharomyces cerevisiae. The soluble phosphorylated glucans are useful for prophylactic and therapeutic applications against neoplastic, bacteria, viral, fungal and parasitic diseases. The soluble phosphorylated glucans are used either alone or in combination with a known antimicrobial agent for prophylactic and therapeutic antimicrobial applications. Additionally, they may be administered as a non-toxic adjuvant, in combination with chermotherapy. The soluble phosphorylated glucans are also useful for stimulating macrophage cells, either in vivo or in vitro, to produce a cytotoxic/cyctostatic factor effective against cancer cells.
Inventors
- 👤 David L. Williams
- 👤 I. William Browder
- 👤 Nicholas R. Diluzio, deceased
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 18:26
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; C; C08; C08B; C08B37/00; C08B37/0006; C08B37/0024; A61P; A61P31/00; A61P31/04; A61P35/00; A61P37/00; C07; C07H; C07H3/00; C07H3/06; C12; C12P; C12P19/00; C12P19/04
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
80 words
A method for treatment of an infection in animals or humans, comprising: administering to an animal or a human affected with said infection a therapeutically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human.
Claim 2
Independent Claim
80 words
A method for treatment of an infection in animals or humans, comprising: administering to an animal or a human affected with said infection a therapeutically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human.
Claim 3
Dependent Claim
30 words
The method according to claim 1, in which the soluble glucan is further characterized by the substantially complete absence of triple helical chains as determined by nuclear magnetic resonance spectroscopy.
Claim 4
Dependent Claim
27 words
The method according to claim 1, in which the soluble glucan is further characterized by having a degree of phosphorylation ranging from about 1.4% to about 3.4%.
Claim 5
Dependent Claim
27 words
The method according to claim 1, in which the soluble glucan is further chracterized by having a molecular weight ranging from about 10,000 to about 100,000 daltons.
Claim 6
Dependent Claim
27 words
The method according to claim 1, in which the soluble glucan is further characterized by having a molecular weight ranging from about 100,000 to about 500,000 daltons.
Claim 7
Dependent Claim
19 words
The method according to claim 1, in which the soluble glucan is which is obtained from a microbial source.
Claim 8
Dependent Claim
15 words
The method according to claim 1, in which the infection is caused by a bacterium.
Claim 9
Dependent Claim
34 words
The method according to claim 7, in which the bacterium is selected from the group consisting of Staphylococcus aureus, Streptococcus pneumoniae, Mycobacterium tuberculosis, Hemophilus influenzae, Escherichia coli, Bacterium enteritis, Francisella tularensis, and Mycobacterium leprae.
Claim 10
Dependent Claim
15 words
The method according to claim 1, in which the infection is caused by a virus.
Claim 11
Dependent Claim
18 words
The method according to claim 9, in which the virus comprises Herpes simplex I or II or Hepatitis.
Claim 12
Dependent Claim
15 words
The method according to claim 1, in which the infection is caused by a fungus.
Claim 13
Dependent Claim
16 words
The method according to claim 11, in which the fungus comprises Candida albicans or Sporotrichium schenkii.
Claim 14
Independent Claim
77 words
A method for the prevention of an infection in animals or humans, comprising: administering to such an animal or a human a prophylactically effective amount of soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human.
Claim 15
Independent Claim
77 words
A method for the prevention of an infection in animals or humans, comprising: administering to such an animal or a human a prophylactically effective amount of soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human.
Claim 16
Dependent Claim
30 words
The method according to claim 13, in which the soluble glucan is further characterized by the substantially complete absence of triple helical chains as determined by nuclear magnetic resonance spectroscopy.
Claim 17
Dependent Claim
26 words
The method according to claim 13, which the soluble glucan is further characterized by having a degree of phosphorylation ranging from about 1.4% to about 3.4%.
Claim 18
Dependent Claim
27 words
The method according to claim 13, in which the soluble glucan is further chracterized by having a molecular weight ranging from about 10,000 to about 100,000 daltons.
Claim 19
Dependent Claim
27 words
The method according to claim 13, in which the soluble glucan is further characterized by having a molecular weight ranging from about 100,000 to about 500,000 daltons.
Claim 20
Dependent Claim
17 words
The method according to claim 13, in which the soluble glucan is obtained from a microbial source.
Claim 21
Dependent Claim
15 words
The method according to claim 13, in which the infection is caused by a bacterium.
Claim 22
Dependent Claim
34 words
The method according to claim 19 in which the bacterium is selected from the group consisting of Staphylococcus aureus, Streptococcus pneumoniae, Mycobacterium tuberculosis, Hemophilus influenzae, Escherichia coli, Bacterium enteritis, Francisella tularensis, and Mycobacterium leprae.
Claim 23
Dependent Claim
15 words
The method according to claim 13, in which the infection is caused by a virus.
Claim 24
Dependent Claim
18 words
The method according to claim 21, in which the virus comprises Herpes simplex I or II or Hepatitis.
Claim 25
Dependent Claim
15 words
The method according to claim 13, in which the infection is caused by a fungus.
Claim 26
Dependent Claim
16 words
The method according to claim 23, in which the fungus comprises Candida albicans or Sporotrichium schenkii.
Claim 27
Dependent Claim
25 words
The method according to claim 1, in which the glucan is administered intradermally, intravenously, intraperitoneally, subcutaneously, orally, topically, topically to nasal linings or by inhalation.
Claim 28
Dependent Claim
25 words
The method according to claim 13, in which the glucan is administered intradermally, intravenously, intraperitoneally, subcutaneously, orally, topically, topically to nasal linings or by inhalation.
Claim 29
Independent Claim
89 words
A method for treatment of an infection in animals or humans, comprising: administering to an animal or a human affected with said infection a therapeutically effective amount of a composition which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogeric and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human, in combination with an antimicrobial agent effective against the infection.
Claim 30
Independent Claim
89 words
A method for treatment of an infection in animals or humans, comprising: administering to an animal or a human affected with said infection a therapeutically effective amount of a composition which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogeric and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human, in combination with an antimicrobial agent effective against the infection.
Claim 31
Dependent Claim
25 words
The method according to claim 27, in which the composition is administered intradermally intravenously, intraperitoneally subcutaneously, orally, topically, topically to nasal linings or by inhalation.
Claim 32
Independent Claim
85 words
A method for the prevention or treatment of an opportunistic infection in animals or humans which are immunosuppressed, comprising: administering to an immunosuppressed animal or human a prophylactically or therapeutically effective amount of a souluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human.
Claim 33
Independent Claim
85 words
A method for the prevention or treatment of an opportunistic infection in animals or humans which are immunosuppressed, comprising: administering to an immunosuppressed animal or human a prophylactically or therapeutically effective amount of a souluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human.
Claim 34
Dependent Claim
80 words
A pharmaceutical composition for the prevention or treatment of an infection in animals or humans, comprising: a therapeutically or prophylactically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human, and a physiologically acceptable carrier.
Claim 35
Dependent Claim
80 words
A pharmaceutical composition for the prevention or treatment of an infection in animals or humans, comprising: a therapeutically or prophylactically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a pronouced immunobiological response when administered in vivo to an animal or to a human, and a physiologically acceptable carrier.
Claim 36
Dependent Claim
15 words
The composition according to claim 30, further comprising an antimicrobial agent effective against the infection.
Claim 37
Dependent Claim
14 words
The composition according to claim 31, in which the antimicrobial agent is an aminoglycoside.
Claim 38
Dependent Claim
12 words
The composition according to claim 32, in which the aminoglycoside is gentamicin.
References Cited (Backward Citations)
US3081226A
Cited
US4493894A
Cited
US4138479A
Cited
US4225673A
Cited
US4237266A
Cited
US4396611A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-02 | 1992-02-01 | 1992-08-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-02 | 1996-02-01 | 1996-08-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-02 | 2000-02-01 | 2000-08-02 | $7700.00 | Window Closed / Lapsed |